Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Long-Term Investments (2021 - 2023)

Cullinan Therapeutics (CGEM) has 3 years of Long-Term Investments data on record, last reported at $13.5 million in Q3 2023.

  • For Q3 2023, Long-Term Investments fell 53.95% year-over-year to $13.5 million; the TTM value through Sep 2023 reached $13.5 million, down 53.95%, while the annual FY2022 figure was $80.9 million, 42.39% down from the prior year.
  • Long-Term Investments reached $13.5 million in Q3 2023 per CGEM's latest filing, down from $20.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $140.4 million in Q4 2021 and bottomed at $13.5 million in Q3 2023.
  • Average Long-Term Investments over 3 years is $73.6 million, with a median of $80.9 million recorded in 2022.
  • The widest YoY moves for Long-Term Investments: up 193.29% in 2022, down 76.34% in 2022.
  • A 3-year view of Long-Term Investments shows it stood at $140.4 million in 2021, then crashed by 42.39% to $80.9 million in 2022, then plummeted by 83.25% to $13.5 million in 2023.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $13.5 million in Q3 2023, $20.3 million in Q2 2023, and $110.4 million in Q1 2023.